Our Mission

Established in 2013, the Oklahoma Clinical and Translational Science Institute serves as a catalyst for clinical and translational research that improves health and healthcare for underserved and underrepresented populations, to provide training and infrastructure to help junior investigators to launch independent research careers, and to expand the opportunities of IDeA states and Oklahoma communities to participate in research that improves the health of our residents. 

Oklahoma Shared Clinical and Translational Resources

OSCTR is Oklahoma's NIH-funded IDeA-CTR that provides resources, information, and training to help individuals or communities involved in performing clinical and translational research in the state

Oklahoma Primary Healthcare Improvement Cooperative

 

OPHIC is the implementation science arm of a statewide network to help improve healthcare delivery assisting primary care practices to adopt evidence-based best practices for the care of their patients.

OCTSI Clinical Research Unit

​​

The OCTSI CRU assists medical providers to identify and conduct clinical research opportunities in Oklahoma.

University of Oklahoma Health Sciences Receives Federal Funding to Improve Health Care Access Across the State

Across large areas of Oklahoma and the nation, primary care clinics are a lifeline, providing care for people who otherwise would have to travel many miles to see a doctor. To increase access to vital health care, the National Institutes of Health announced an ambitious new initiative to integrate NIH-funded clinical trials into routine patient care in medically underserved areas like rural Oklahoma and within Tribal nations.

OU Awarded $17 Million NIH Grant to Improve Cancer Outcomes Among Native Americans

The National Institutes of Health has awarded the University of Oklahoma a five-year, $17.2 million grant to partner with tribal nations and communities to improve cancer outcomes. Research has shown that the American Indian and Alaska Native population in Oklahoma experiences a 36% higher incidence of cancer and a 73% higher death rate from cancer than faced by the U.S. general population.

OCTSI Director elected to National Academy of Medicine

Judith A. James, M.D., Ph.D., associate vice provost for clinical and translational science and professor of medicine at the University of Oklahoma Health Sciences Center, has been elected to the National Academy of Medicine for her work in the field of autoimmunity and autoimmune disorders.

She is the first woman from an Oklahoma institution – and fifth overall Oklahoma-based scientist – to be selected for this prestigious honor, which is widely considered one of the highest honors in the fields of health and medicine.

BERD Short Course on Biases in Diagnostic and Prognostic Research

https://osctr.ouhsc.edu/short-course

This seminar/workshop will provide a brief overview of study designs for and common biases affecting diagnostic test accuracy and prognostic studies.  Numerical examples  will be used to illustrate the impact of common biases.

3/31/2023 Noon - 1:30 pm (CDT)

Hudson College of Public Health Auditorium (CHB 150)

Lunch Provided for first 25 in-person participants

Registration Link

Oklahoma Shared Clinical and Translational Resources Community-Engaged Research Exploratory (CERE) Awards

This program is intended to support community engagement to develop funded research partnerships. Funds can be used for research development activities, including convening partners, working with individuals pursuing related work, and conducting needs assessments in community settings. The funds cannot be used to support actual human-subjects research protocols, which can be funded under other OSCTR pilot research programs and/or external funding.

Subscribe to News

Recent Publications

Experimental induction of anti-muscarinic type-3-receptor extracellular loop antibodies by immunization with 4-hydroxy-2-nonenal modified Ro60 and unmodified Ro60

Clin Exp Immunol. 2025 Jan 21;219(1):uxae114. doi: 10.1093/cei/uxae114.

ABSTRACT

OBJECTIVE: Sjögren's Disease (SjD) subjects have decreased lacrimal/salivary gland function. Studies have proposed that autoantibodies targeting G-protein-coupled muscarinic acetylcholine-type-3-receptor (M3R) are potential clinical markers for SjD. We hypothesized that rabbits/mice immunized with 4-hydroxy-2-nonenal (HNE)-modified/unmodified Ro60 will develop an autoimmunity, specifically a SjD phenotype, thus expressing increased levels of anti-M3R antibodies.

Impact of COVID-19 Diagnosis on Weight Trajectories of Children in the US National COVID Cohort Collaborative

medRxiv [Preprint]. 2025 Jan 5:2025.01.03.25319927. doi: 10.1101/2025.01.03.25319927.

ABSTRACT

BACKGROUND: The COVID-19 pandemic has exacerbated the obesity epidemic, with both adults and children demonstrating rapid weight gain during the pandemic. However, the impact of having a COVID-19 diagnosis on this trend is not known.

Media